Exenatide
As of the edition of 20 October 2026, Exenatide is a protein: marketed, first approved in 2005 (US); acts on GLP1R; US protection ended in 2025.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2010
- Kind
- Protein
- Brand name
- Byetta
- First approved
- 28 April 2005 (US)
- Approvals on record
- 8 in 2 regions
- Holder of the most recent approval
- AstraZeneca; 3 holders in all
- Withdrawn from market
- 1 January 2026 (in some regions)
- Registered trials
- 229, 27 stopped early
- Disease areas
- Nutrition and metabolism; Hormones; Urinary and reproductive; Pregnancy and women's health; Heart and blood vessels; Nervous system
US protection
US protection ended in 2025.
The last listed US drug-substance patent ended in 2025. The application that gives this date is held by AstraZeneca.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product3 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 3 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Exenatide.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| GLP1R | Glucagon-like peptide 1 receptor | P43220 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 33 | 25 | 2 | 1 |
| Phase 1 | 25 | 20 | 0 | 4 |
| Phase 2 | 38 | 29 | 0 | 5 |
| Phase 3 | 66 | 56 | 0 | 6 |
| Phase 4 | 67 | 46 | 1 | 11 |
| All trials | 229 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| AstraZeneca | Acquired holder and Lead sponsor of trials | 2002 to now |
| Eli Lilly | Applicant and Lead sponsor of trials | 2010 to now |